Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal

ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain–Barré syndrome 7 days followi...

Descripción completa

Detalles Bibliográficos
Autores principales: Luitel, Prajjwol, Poudel, Bibek, Upadhyay, Devansh, Paudel, Sujan, Tiwari, Nishan, Gajurel, Bikram Prasad, Karn, Ragesh, Rajbhandari, Reema, Shrestha, Aashish, Gautam, Niraj, Ojha, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130842/
https://www.ncbi.nlm.nih.gov/pubmed/35646371
http://dx.doi.org/10.1177/2050313X221100876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130842/
https://www.ncbi.nlm.nih.gov/pubmed/35646371
http://dx.doi.org/10.1177/2050313X221100876

Ejemplares similares